Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse hemodynamic effects  by Cohen, Michael V. et al.
I [ 
INTRAVENOUS CO-INFUSION OF ADENOSINE AND NOREPINEPHRINE PRECONDITIONS THE 
HEART WITHOUT ADVERSE HEMODYNAMIC EFFECTS 
Michael V. Cohen, MD 
Jon D. Thornton, MD, PhD 
Christy S. Thornton, MD 
Hiroshi Sato, PhD 
Takayuki Miki, MD 
James M. Downey, PhD 
Objective: A simple intervention is needed that could protect the heart 
against infarction during limited-access coronary artery bypass grafting. 
Adenosine and norepinephrine can precondition the heart with resulting 
protection, but adverse hemodynamic effects prevent clinical application. 
Because heart rate, blood pressure, and contractility effects of these two 
drugs are diametrically opposite, a mixture might be beneficial. Methods: A 
superficial branch of the left coronary artery of rabbits was surrounded 
with a suture. Infarction was produced in all hearts by a 30-minute 
coronary artery occlusion. Infarct size after reperfusion was measured and 
is presented as a percentage of the risk zone. The effect of 5-minute 
intravenous co-infusion of adenosine (20 mg/kg) and norepinephrine (0.1 
mg/kg) 15 minutes before ischemia was examined. In addition, the protec- 
tive effect of three Sequential intravenous bolus injections of adenosine at 
either 0.2 or 0.4 mg/kg was evaluated. Results: Thirty minutes of regional 
ischemia caused infarction of 40% - 4% of the risk zone. The combination 
of adenosine and norepinephrine caused no change in blood pressure but 
rather protected the heart, with infarction of only 9% - 2% of the risk zone 
(p = 0.0001 vs control). Adenosine-norepinephrine co-infusion still pro- 
tected the heart when the interval between infusion and ischemia was 
extended to 60 minutes, but it did not protect with a 120-minute interval. 
Intravenous bolus injections of adenosine resulted in cardiac slowing and 
marked hypotension. Boluses of 0.2 mg/kg resulted in a minimal, but 
significant, reduction in infarct size, whereas the higher dose provided no 
protection. Conclusion: Adenosine-norepinephrine co-infusion provides a 
feasible and safe parenteral method for preconditioning the heart. 
(J Thorac Cardiovasc Surg 1997;114:236-42) 
L imited-access myocardial revascularization 1 is in- creasing in popularity because of diminished 
postoperative discomfort and complications and re- 
duced hospital stays. Unfortunately, traditional 
methods of myocardial preservation with cardiople- 
gia cannot be used in these patients because the 
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heart is maintained in a normothermic and beating 
state. An alternative method of cardiac protection 
might be preconditioning with either ischemia or 
pharmacologic agents. Ischemic preconditioning has 
received much attention since its initial description 
in 1986 by Murry and associates. 2 Paradoxically, 
brief episodes of ischemia enable the myocardium to 
better withstand a subsequent period of ischemia, 
resulting in a marked resistance against infarction. 
In addition to reduced infarction, preconditioning 
may also improve recovery of postischemic ventric- 
ular function 3 and diminish the incidence of malig- 
nant ventricular arrhythmias both during ischemia 
and after reperfusion. 4' 5 
The mechanism of this protection has been ea- 
gerly sought. In rats 6 and rabbits, 7protein kinase C 
activation appears to be critical to the protection. 
Furthermore, in the rabbit agonists to any of the 
cardiac receptors that are coupled to protein kinase 
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C, including the adenosine A1, s the ~l-adrenergic, s 
the bradykinin B2, s the angiotensin I! AT1, s the 
muscarinic M2, 9 the endothelin ET-1,1° and the 
opioid ~ or K 11 receptors, can trigger protection in 
lieu of brief ischemia. Interestingly, in the rat an 
opioid 12 rather than adenosine j3 appears to be the 
principal trigger. 
Previously reported successful ischemic precondi- 
tioning before coronary revascularization has in- 
volved brief periods of aortic crossclamping before 
more prolonged intervals of ischemic arrest. 14 How- 
ever, this technique is not possible during limited- 
access surgery. Although brief occlusions of the 
isolated left anterior descending coronary artery 
could be used to precondition a portion of the 
myocardium, it would be better to pharmacologi- 
cally protect the myocardium in a global fashion 
before any manipulation of the coronary artery. 
Unfortunately, all of the known pharmacologic trig- 
gers of preconditioning 7' 15, 16 cause either unaccept- 
able hypotension (adenosine, carbachol, and brady- 
kinin) or hypertension (~l-agonists, angiotensin II, 
and endothelin-1), are carcinogenic (phorbol es- 
ters), or induce serious pulmonary disease (sodium 
oleate). Although intracoronary bradykinin might 
be capable of preconditioning the heart with mini- 
mal adverse hemodynamic effects, 17 the require- 
ment for selective infusion into a coronary artery to 
minimize the amount of drug reaching the periph- 
eral vasculature limits the usefulness of this ap- 
proach. 
Although both adenosine is and norepineph- 
rine19, 2o can trigger protection, they have opposite 
effects on heart rate, contractility, and blood pres- 
sure. The object of this study was to see whether we 
could induce protection by co-infusion of these two 
agents into a peripheral vein at doses that produced 
equivalent but opposing effects on hemodynamics. If 
such a mixture could be achieved, then it might well 
be possible to precondition the heart of the patient 
with cardiac disease by means of intravenously 
administered drugs with minimal hemodynamic side 
effects. 
Methods 
All experiments were performed in accordance with the 
"Guide for the Care and Use of Laboratory Animals" 
(National Academy Press, Washington, revised 1996) and 
were approved by the Institutional Animal Care and Use 
Committee of the University of South Alabama. 
Surgical procedures. New Zealand White rabbits of 
either sex, weighing between 1.4 and 3.5 kg, were anes- 
thetized with intravenous sodium pentobarbital (30 rag/ 
kg). The trachea was intubated through acervical incision, 
and the animals' lungs were mechanically ventilated with 
a positive-pressure respirator (MD Industries) and 100% 
oxygen with an initial tidal volume of 15 ml and a rate of 
30 breaths/min. The respiratory rate was adjusted to keep 
blood pH in the physiologic range. Body temperature was 
maintained near 38 ° C with a heating pad. A carotid artery 
and jugular vein were cannulated for blood pressure 
monitoring and additional anesthesia and drug adminis- 
tration, respectively. A left thoracotomy was performed in
the fourth intercostal space, and the pericardium was 
opened to expose the heart. A 2-0 silk suture on a curved 
taper needle was passed around a prominent branch of 
the left coronary artery, and the ends were pulled through 
a small vinyl tube to form a snare. The coronary branch 
was occluded by pulling the snare, and myocardial isch- 
emia was confirmed by the appearance of regional cyano- 
sis. Reperfusion was achieved by releasing the snare and 
was documented by visible hyperemia of the surface of the 
heart. 
Infarct size measurement. At the end of the experi- 
ment hearts were quickly excised, mounted on a Langen- 
dorff apparatus, and perfused at room temperature with 
saline solution for 1 minute to wash out blood. The 
coronary artery was then reoccluded, and 1 to 10/xm zinc 
cadmium sulfide fluorescent particles (Duke Scientific) 
were infused to demarcate the risk zone as the nonfluo- 
rescent region. The heart was weighed, frozen, and then 
cut into transverse slices approximately 2 mm thick. The 
slices were thawed and stained by incubation for 20 
minutes at 37°C in 1% triphenyltetrazolium chloride in 
pH 7.4 buffer. The areas of infarct (tetrazolium negative) 
and risk zone (nonfluorescent under ultraviolet light) 
were determined by planimetry. Infarct and risk zone 
volumes were then calculated by multiplying each area by 
the slice thickness and summing the products. Infarct size 
was expressed as a percentage of the risk zone infarcted. 
Protocols. All rabbits were subjected to 30 minutes of 
regional ischemia followed by 180 minutes of reperfusion. 
A control group of rabbits was subjected only to this 
ischemia-reperfusion sequence. In the second group of 
rabbits (NE group), norepinephrine, 0.1 mg/kg, was in- 
fused over 5 minutes starting 15 minutes before the 
30-minute ischemic insult. Co-infusion of norepinephrine, 
0.1 mg/kg, and adenosine, 20 mg/kg, was performed in the 
third group (NE-ADO group). This dose of adenosine was 
determined to be one that countered the hypertensive 
effect of the adrenergic agonist. These two agents were 
co-infused over 5 minutes, and administration ceased 10 
minutes before the long coronary occlusion. So that we 
could determine how long the combined norepinephrine 
and adenosine ffect persisted, the drug-free interval 
between the 5-minute drug infusion and the 30-minute 
coronary occlusion was lengthened first to 60 minutes 
(NE+ADO-60) and then 220 minutes (NE+ADO-120) in 
two additional groups of rabbits. 
Two other groups of rabbits were studied. In one 
group, three sequential intravenous boluses of adeno- 
sine, 0.2 mg/kg, were administered before the 30- 
minute coronary occlusion; in the second group, the 
dose of adenosine was doubled to 0.4 mg/kg. After each 
injection, a 5-minute recovery period was permitted 
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Table I. Effect of norepinephrine and adenosine on heart rate and blood pressure 
Baseline Drug(s) 30 min after drug(s) 
HR MAP Hr MAP HR MAP 
(beats/rain) (ram Hg) (beats~rain) (mm Hg) (beats/min) (mrn Hg) 
Occlusion Reperfusion 
HR MAP HR MAP 
(beats~ruin) (ram Hg) (beats~rain) (ram Hg) 
Control 275.1 _+ 14.9 60.0 ± 4.0 - -  - -  
NE  256.0 ± 11.5 59.8 ± 2.6 260.6 _+ 10.3 115.8 + 6.7* 
NE+ADO 239.6 ± 13.3 69.2 ± 5.0 203.9 _+ 8.4t 62.9 ± 7.2 
NE+ADO-60 241.1 ± 12.2 56.1 ± 3.1 224.1 + 8.9t 51.2 -+ 2.1 
NE+ADO-120 261.2 _+ 7.7 56.2 -+ 4.1 243.5 ± l l .0 t  54.2 ± 2.6 
- -  - -  263.1 _+ 14.5 58.4 ± 3.4 266.9 -+ 16.6 60.9 ± 4.6 
- -  - -  240.6 ± 10.1 50.8 --+ 3.4 243.1 + 10.0 56.6 ± 1.9 
- -  - -  247.6 _+ 12.4 56.0 ± 3.5 246.1 ± 8.6 60.7 -+ 2.1 
239.9 ± 11.7 59.5 ± 3.5 234.1 -+ 17.4 51.6 -+ 2.5 258.3 ± 29.5 57.4 -+ 3.3 
271.2 ± 13.0 58.7 -+ 3.5 250.0 ± 20.4 52.0 ± 1.5 244.8 -+ 11.9 47.6 -+ 3.2 
Values are mean -- standard error of the mean. Measurements were made at the end of the drug infusion, after 30 minutes of coronary occlusion, and after 
60 minutes of reperfusion. ADO, Adenosine; ADO-60, 120, 60- and 120-minute drug-free interval between end of drug infusion and onset of 30-minute 
coronary occlusion; FIR heart rate; MAP, mean arterial pressure; NE, norepinephrine. Statistical significance of difference between experimental observation 
and baseline: *p < 0.001; tp < 0.01. 
Table II. Effect of intravenous boluses of adenosine on heart rate and blood pressure 
Baseline Drug Occlusion Reperfusion 
HR MAP HR MAP HR MAP HR MAP 
(beats~rain) (turn Hg) (beats~rain) (ram Hg) (beats~ruin) (rnrn Hg) (beats~rain) (ram Hg) 
Contro l  264.8 ± 12.7 86.9 -+ 5.0 - -  - -  260.6 _+ 12.8 75.3 ± 5.0 266.0 -+ 17.0 73.3 -- 4.5 
ADO-0 .2  251.3 _+ 5.4 71.2 _+ 4.0 220.7 _+ 5.2* 41.5 ± 3 .1 '  243.9 _+ 7.3 62.3 ± 3.4t  240.4 _+ 8.3 63.0 _+ 3.2 
ADO-0 .4  244.0 _+ 8.5 78.2 ± 4.6 208.7 _+ 11.2:) 41.2 ± 1.4" 246.3 _+ 9.0 68.7 _+ 3.9§ 235.7 + 10.5 52.9 _+ 3.9§ 
Values are mean _+ standard error of the mean. Peak drug effects were measured. Other measurements were made at the end of the 30-minute coronary 
occlusion and after 60 minutes of reperfusion. For abbreviations see Table I. Statistical significance of difference between observation and baseline: *p < 
0.005; :~p < 0.05. Statistical significance of difference between control and treatment groups: tP < 0.001; §p < 0.05. 
before the next injection. Five minutes after adminis- 
tration of the third bolus, the coronary artery was 
occluded as detailed earlier. 
Statistics. All data are presented as mean -+ standard 
error of the mean. One-way analysis of variance combined 
with Tukey's post-hoc test was used to test for differences 
in infarct size between groups. Analysis of variance with 
replication was used to test for differences inhemodynam- 
ics in any given group. When a significant group difference 
was detected, observations atindividual time pointswere 
compared with paired t tests by means of a Dunn-Sid~k 
correction for multiple comparisons. 
Results 
Thirty-seven rabbits were successfully prepared 
for the protocols designed to evaluate the efficacy of 
co-infusion of norepinephrine and adenosine. As 
demonstrated in Table I, hemodynamics before 
treatment were comparable in all groups. Intrave- 
nous norepinephrine significantly raised mean arte- 
rial blood pressure from 59.8 to 115.8 mm Hg (p = 
0.0003). This doubling of pressure was not accom- 
panied by any significant change in heart rate. 
Co-infusion of this same dose of norepinephrine 
and adenosine caused no significant change in blood 
pressure (69.2 to 62.9 mm Hg, p = 0.83), but it did 
have a small bradycardic effect (p = 0.04). Similar 
changes were observed in the NE+ADO-60 and 
NE+ADO-120 groups. All hemodynamic changes 
regressed quickly after discontinuation of the 
infusions. Hemodynamics were not significantly 
altered during coronary occlusion and subsequent 
reperfusion. Blood pressure was lowest at the 
termination of the 3-hour reperfusion period in 
the NE+ADO-120 rabbits, probably because 
those preparations were evaluated for 1 to 2 hours 
longer than the others. 
Twenty-five rabbits were successfully prepared 
for study of the effects of sequential intravenous 
bolus injections of adenosine, including a second 
control group. Baseline heart rates presented in 
Table II for these three groups were similar to 
those reported in Table I, whereas blood pres- 
sures were modestly higher. Blood pressure de- 
clined after each bolus of adenosine by an average 
of 30 to 35 mm Hg, and heart rate decreased by 30 
to 40 beats/min. Changes were similar in the low- 
and high-dose groups. Hemodynamics always re- 
turned to baseline levels within 2 minutes and, 
therefore, before the next bolus injection or the 
coronary occlusion. 
Infarct data from the first five groups of hearts are 
presented in Table III and Fig. 1. Heart weight and 
risk zone sizes did not differ significantly among the 
groups. The risk zone for the NE+ADO-120 rabbits 
tended to be smaller, but the difference was not 
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Fig. 1. Infarct size normalized as percent infarction of 
the risk zone. Open symbols indicate individual experi- 
ments and solid symbols indicate the group means and 
standard error of the mean. Note that protection is 
beginning to wane 60 minutes after treatment with a 
combination ofnorepinephrine (NE) and adenosine (AD) 
and is completely absent 120 minutes after treatment. 
significant (p ranged from 0.12 to 0.57 for compar- 
isons with the other four groups). Infarction aver- 
aged 40.0% +_ 4.2% of the risk zone in control 
animals. A 5-minute infusion of norepinephrine 
alone decreased infarct size to 10.2% 2 2.7% (p = 
0.0001). Salvage was similar in rabbits treated with 
both norepinephrine and adenosine (infarct size 
8.9% -+ 2.3% of risk zone, p = 0.0001 vs control). As 
the drug-flee interval between termination of the 
norepinephrine-adenosine infusion and the onset of 
the 30-minute coronary occlusion increased, protec- 
tion waned. Some protection remained after a 60- 
minute drug-flee interval (p = 0.002). However, 
when the interval was extended to 2 hours, infarc- 
tion was not different from that observed in control 
animals (p = 0.72). Fig. 2 and Table IV show the 
infarct data in the rabbits treated with intravenous 
boluses of adenosine. Although the hearts in the 0.4 
mg/kg adenosine treatment group were modestly 
larger than those in the control group, the risk zone 
volumes were comparable in all three groups. In the 
control group, infarct size averaged 37.2% _+ 2.0% 
of the risk zone, similar to that measured in the 
other control group. With the smaller dose of aden- 
osine, infarction averaged 25.4% _+ 3.1% of the risk 
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Fig. 2. Infarct size normalized as percent infarction of 
the risk zone. Open symbols indicate individual experi- 
ments and solid symbols indicate the group means and 
standard error of the mean. Three successive boluses of 
adenosine (AD-0.2), 0.2 mg/kg, produced a very small, but 
significant, protective effect (p < 0.025 vs control). On the 
other hand, the higher dose (AD-0.4) of 0.4 mg/kg had no 
salutary effect. 
zone. This infarct size was only minimally less than 
that observed in untreated rabbits, but the differ- 
ence was significant (p = 0.02). The larger dose of 
adenosine clearly had no effect on infarct size (p = 
0.72). 
Discussion 
Ischemic preconditioning can salvage jeopardized 
myocardium in all experimental animal species 
tested to date: rat, 13 rabbit, 18 pig, m and dog. 2 Fur- 
thermore, isolated human ventricular myocytes can 
be preconditioned, 22 and ischemic preconditioning 
has also been shown to be a clinical phenome- 
non.14, 23-26 Preconditioning would be ideal for pro- 
tection of hearts of patients undergoing limited- 
access myocardial revascularization in which 
traditional cardioplegic agents cannot be used. 
However, its use would not be precluded in patients 
undergoing a midline sternotomy needed for more 
extensive myocardial revascularization, even when 
cardioplegia can be used. If a coronary artery must 
be occluded or flow stopped, myocardial necrosis 
may develop. The latter may be attenuated with a 
preconditioning protocol. 
As noted earlier, multiple pharmacologic agents 
can trigger preconditioning in experimental models 
of myocardial ischemia nd infarction, but none has 
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Table III. Effect of norepinephrine and adenosine on infarct size 
B W HW Risk zone Infarct I/R 
N (kg) (gin) (crn 3) (cm 3) (%) 
Control  8 2.3 _+ 0.2 7.0 -+ 0.3 0.76 + 0.05 0.31 + 0.05 40.0 _+ 4.2 
NE  8 1.8 _+ 0.1 6.4 _+ 0.4 0.68 + 0.05 0.07 -+ 0.02* 10.2 _+ 2.7* 
NE+ADO 9 2.0 _+ 0.2 7.2 _+ 0.4 0.84 + 0.05 0.08 + 0.02* 8.9 -- 2.3* 
NE+ADO-60 8 2.0 + 0.1 6.8 + 0.3 0.88 --- 0.09 0.15 -- 0.04? 17.9 _+ 4.0* 
NE+ADO-120 4 1.8 _+ 0.1 6.8 _+ 0.2 0.57 --- 0.11 0.18 -+ 0.05 32.0 + 5.6 
Values are mean -- standard error of the mean. For abbreviations see Table I. BW, Body weight; HW,, heart weight; I/R, infarct/risk zone ratio; N, number 
of animals. Statistical significance of difference between experimental group and control: *p < 0.005; tp < 0.05. 
Table IV. Effect of intravenous boluses of adenosine on infarct size 
BW HW Risk zone Infarct I/R 
N (kg) (gm) (crn 3) (cm 3) (%) 
Control  8 2.0 _+ 0.1 6.7 _+ 0.2 0.97 + 0.08 0.37 + 0.05 37.2 _+ 2.0 
ADO-0.2 11 2.3 _+ 0.0" 7.5 _+ 0.4 0.89 _+ 0.07 0.23 + 0.03 25.4 + 3.17 
ADO-0.4 6 2.2 + 0.1 8.2 _+ 0.4~: 1.06 _+ 0.10 0.35 + 0.06 31.0 _+ 3.6 
Values are mean -+ standard error of the mean. For abbreviations see Tables I and IU. Statistical significance of difference between experimental group and 
control: *p < 0.005; ?p < 0.025; Sp < 0.05. 
been considered for clinical use because of unac- 
ceptable side effects. Adenosine is the prototypical 
preconditioning a onist. Its endogenous production 
by ischemic myocytes i considered to be the major 
trigger of ischemic preconditioning. 15 Although ex- 
ogenous adenosine (1.4 rag) can trigger protection 
and significantly diminish infarct size in the isolated 
rabbit heart in which peripheral hemodynamic ef- 
fects are absent, an intravenous infusion of 5 mg 
delivered over 5 minutes reduced blood pressure 
from 94 to 51 mm Hg in in situ hearts and failed to 
protect them. is In the present experiments, we 
found that boluses of adenosine induced modest 
bradycardia and often severe hypotension. Because 
only the lower dose resulted in minimal, but signif- 
icant, protection, it is uncertain whether the latter 
was related to the exogenously infused adenosine. In
some animals the adenosine decreased the blood 
pressure to less than 30 mm Hg, and this fall may 
have been sufficient o induce enough myocardial 
ischemia to trigger the preconditioning phenome- 
non. The range of infarct sizes in this group, as 
depicted in Fig. 2, suggests that only three of the 11 
hearts showed some evidence of protection, again 
implying that a factor additional to the exogenously 
administered a enosine may well have been opera- 
tional. Endogenous oq-adrenergic stimulation does 
not play a physiologic role in ischemic precondition- 
ing in the rabbit, ~9' 27 but phenylephrine, 27 norepi- 
nephrine released by tyramine administration, 19 and 
exogenous norepinephrine 2° are all capable of trig- 
gering protection. Intravenously administered %- 
agonists, however, produce peripheral arteriolar va- 
soconstriction with unacceptable hypertension. 
Because of the largely opposing hemodynamic 
effects of adrenergic and adenosine agonists, we 
hypothesized that a combination ofthe two might be 
capable of triggering cardioprotection while having 
little net hemodynamic effect. In the present exper- 
iments the norepinephrine-adenosine cocktail sal- 
vaged ischemic myocardium to an extent compara- 
ble with that seen with norepinephrine alone 19' 20 or 
after brief episodes of ischemia. 18 Blood pressure 
was unaffected, however, and the bradycardic effect 
was small. Like ischemic preconditioning, the pro- 
tection persisted long after the infusion was discon- 
tinued. Protection only partially waned if coronary 
occlusion was delayed for 60 minutes after cessation 
of drug infusion, and it disappeared if 2 hours 
elapsed between infusion and occlusion. This time 
course matches that already reported for ischemic 
preconditioning. 2s Although the drug cocktail suc- 
cessfully diminished infarction, neither effects on 
arrhythmias nor myocardial stunning could be eval- 
uated with this rabbit infarct model. 
Currently several techniques are in use to slow or 
stop the heart at critical times during the revascu- 
larization procedure when only limited access is 
available. Cooley 1uses a rapid-acting 13-blocker, and 
some surgeons administer adenosine boluses with 
doses comparable with those used in our rabbits. 
The bolus of 0.2 mg/kg would be comparable with 
administration of 14 mg to a 70 kg man, a dose 
typically used for the treatment of supraventricular 
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tachycardia. Adenosine administered in this fashion 
had obvious A 2 and modest A 1 effects. Although 
intravenous adenosine may be successful at decreas- 
ing heart rate, our data suggest hat this regimen 
probably does not reliably precondition the in situ 
heart. 
Both adenosine ~8 and norepinephrine 19 can trig- 
ger the preconditioned state. It is not clear what the 
relative contribution of either was in this study. In 
pilot studies we found that rabbits would not survive 
the adenosine dose of 20 mg/kg used in the present 
investigation when infused alone; thus we cannot 
determine whether sufficient adenosine receptor 
stimulation would have occurred to precondition the 
heart in the absence of the norepinephrine. The 
animals did survive the norepinephrine infusion and 
were protected. This result would suggest that suf- 
ficient norepinephrine was present o precondition 
the heart without need for a second agent. This is 
not surprising, because both norepinephrine and 
adenosine are thought to precondition the heart by 
activating protein kinase C. s Thus in this situation in 
which norepinephrine has already activated enough 
protein kinase C to protect he heart, concomitant 
administration of adenosine would be expected to 
have little additional effect. Because of the marked 
hemodynamic effect of the norepinephrine, wecan- 
not exclude the possibility that the norepinephrine 
infusion actually caused the release of endogenous 
adenosine that could have contributed to the pro- 
tection.29, 3o Whatever the case, the combination of 
the two agonists was sufficient o trigger the precon- 
ditioned state. 
In this study we chose norepinephrine as the 
a~-agonist rather than a more selective agent such as 
phenylephrine. 27 It was considered desirable to have 
an agent with some ~1 activity to counter the 
negative chronotropic and inotropic effects of aden- 
osine. As a result, heart rate changes were attenu- 
ated with a small net bradycardia. Substitution of 
phenylephrine for norepinephrine might slow the 
heart further, which could provide an additional 
technical benefit during surgery. 
The norepinephrine-adenosine cocktail should be 
well tolerated. Both agents are produced by the 
intact organism and, therefore, the risk of unknown 
and undesirable long-term effects is remote. We 
know of no adverse consequences of acute adminis- 
tration. The main advantage of the cocktail is that it 
can be infused intravenously and, if complications 
do develop, the infusion can be easily discontinued. 
Both agents have very short durations of action. We 
suggest hat such a combination of agents could 
prove very useful for triggering of preconditioning in 
settings in which iatrogenic ischemia is planned or is 
unavoidable, as in limited-access coronary bypass 
operations. 
The technical assistance of W. Keyser Impastato is 
gratefully acknowledged. 
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